Showing results (111-120 of 559) with videos related to

Sort By:
Pageof 56
Circulation|July 1, 2016
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 TrialErin A Bohula, Robert P Giugliano, Christian T Ruff, et al.
The American Journal of Cardiology|August 25, 2004
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)C Michael Gibson, Kanwar P Singh, Sabina A Murphy, et al.
American Heart Journal|January 7, 2003
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 RegistryMaria Cecilia Bahit, Christopher P Cannon, Elliott M Antman, et al.
Journal of the American College of Cardiology|September 1, 2004
Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarctionC Michael Gibson, Sabina A Murphy, Ajay J Kirtane, et al.
The American Journal of Cardiology|May 29, 2013
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, et al.
Circulation|March 27, 2002
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factorsFrank M Sacks, Andrew M Tonkin, Timothy Craven, et al.
Clinical Chemistry|December 18, 2008
Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular deathBenjamin M Scirica, Christopher P Cannon, Marc S Sabatine, et al.
Circulation|December 27, 2011
American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)Marc P Bonaca, Stephen D Wiviott, Eugene Braunwald, et al.
Clinical Cardiology|July 5, 2012
Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitusJacob A Udell, Benjamin M Scirica, Eugene Braunwald, et al.
European Heart Journal. Acute Cardiovascular Care|December 19, 2017
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trialSerge Korjian, Eugene Braunwald, Yazan Daaboul, et al.
Pageof 56